Keros Therapeutics (NASDAQ:KROS) Sees Strong Trading Volume

Keros Therapeutics, Inc. (NASDAQ:KROS) shares saw strong trading volume on Friday . 402,610 shares traded hands during trading, an increase of 5% from the previous session’s volume of 383,336 shares.The stock last traded at $51.71 and had previously closed at $50.29.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer started coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target for the company. Finally, Truist Financial reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and an average price target of $88.29.

Keros Therapeutics Stock Performance

The stock has a market capitalization of $1.88 billion, a P/E ratio of -9.77 and a beta of 1.23. The firm’s fifty day simple moving average is $47.35 and its 200 day simple moving average is $55.38.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, May 8th. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.12. The firm had revenue of $0.08 million during the quarter. During the same quarter in the prior year, the company posted ($1.26) earnings per share. The firm’s revenue for the quarter was down 97.3% on a year-over-year basis. Analysts anticipate that Keros Therapeutics, Inc. will post -4.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Parkman Healthcare Partners LLC boosted its position in Keros Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 360,467 shares of the company’s stock worth $14,332,000 after buying an additional 61,992 shares during the period. Platinum Investment Management Ltd. acquired a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $1,944,000. ADAR1 Capital Management LLC acquired a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $27,367,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Keros Therapeutics by 356.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after purchasing an additional 2,702 shares during the period. Finally, Swiss National Bank lifted its position in shares of Keros Therapeutics by 22.0% in the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $3,303,000 after purchasing an additional 9,000 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.